Xiang‐Yang Ye

3.4k total citations · 1 hit paper
79 papers, 2.4k citations indexed

About

Xiang‐Yang Ye is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, Xiang‐Yang Ye has authored 79 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Molecular Biology, 25 papers in Organic Chemistry and 17 papers in Oncology. Recurrent topics in Xiang‐Yang Ye's work include Histone Deacetylase Inhibitors Research (11 papers), Protein Degradation and Inhibitors (11 papers) and PARP inhibition in cancer therapy (9 papers). Xiang‐Yang Ye is often cited by papers focused on Histone Deacetylase Inhibitors Research (11 papers), Protein Degradation and Inhibitors (11 papers) and PARP inhibition in cancer therapy (9 papers). Xiang‐Yang Ye collaborates with scholars based in China, France and United States. Xiang‐Yang Ye's co-authors include Renren Bai, Tian Xie, Yuanyuan Xie, Tian Xie, Jianan Guo, Dan Yang, Ming Xu, Zi Hui, Xingrui He and Yuan Gao and has published in prestigious journals such as Journal of the American Chemical Society, SHILAP Revista de lepidopterología and Biochemistry.

In The Last Decade

Xiang‐Yang Ye

73 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Oxidative stress: The core pathogenesis and mechanism of Alzheimer’s disease

2022 489 citations Renren Bai, Xiang‐Yang Ye et al. profile →

Peers

Countries citing papers authored by Xiang‐Yang Ye

Since Specialization

Citations

This map shows the geographic impact of Xiang‐Yang Ye's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiang‐Yang Ye with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiang‐Yang Ye more than expected).

Fields of papers citing papers by Xiang‐Yang Ye

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiang‐Yang Ye. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiang‐Yang Ye. The network helps show where Xiang‐Yang Ye may publish in the future.

Co-authorship network of co-authors of Xiang‐Yang Ye

This figure shows the co-authorship network connecting the top 25 collaborators of Xiang‐Yang Ye. A scholar is included among the top collaborators of Xiang‐Yang Ye based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiang‐Yang Ye. Xiang‐Yang Ye is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Machine learning prediction of rapid HBsAg seroclearance at week 24 in inactive carriers treated with pegylated interferon 2025 ·Hepatology International ·Jianxia Dong, Shan Ren, Ping Wu, (unknown), (unknown), Jing Zhao, Xiang‐Yang Ye, Yan Huang, Zu‐Jiang Yu, Wen‐Hua Zhang, Yilan Zeng, Xiaozhong Wang, (unknown), Shuangsuo Dang, Jiabin Li, (unknown), Xinyue Chen	0
2	Poly(ADP-ribose) polymerase-1 (PARP1)-based dual inhibitors targeting cancer synthetic lethality (2022-present): advances and perspectives 2025 ·European Journal of Medicinal Chemistry ·(unknown), Yuqing Zhang, (unknown), Miao Yu, Shuxiang Li, Bingyang Du, (unknown), Yuan Gao, Xiang‐Yang Ye	0
3	A novel PARP-ATR dual inhibitor exhibits anti-triple-negative breast cancer activity by inducing excessive DNA damage in the mitotic phase 2025 ·Biochemical Pharmacology ·Chenchen Wang, (unknown), (unknown), Miao He, Pengpeng Zhang, (unknown), Yuan Gao, Xingrui He, Xinyi Shao, (unknown), Zi Hui, Hang Zhang, (unknown), Xiang‐Yang Ye	1
4	Updated patent review for hematopoietic progenitor kinase (HPK1) inhibitors and degraders (2021-present) 2025 ·Expert Opinion on Therapeutic Patents ·(unknown), (unknown), Jing Yue, (unknown), Zi Hui, Hang Yin, Jianshe Wang, Xiang‐Yang Ye	0
5	Development and therapeutic potential of DNA-dependent protein kinase inhibitors 2024 ·Bioorganic Chemistry ·Zi Hui, (unknown), (unknown), Carmen Garrido, Frédéric Lirussi, Xiang‐Yang Ye, Tian Xie, Zhaoqian Liu	2
6	Design, synthesis, and biological evaluation of novel AAK1/HDACs dual inhibitors against SARS-CoV-2 entry 2024 ·Bioorganic Chemistry ·(unknown), Yueying Xu, Xia Yao, (unknown), Zi Hui, (unknown), Chenchen Wang, Jinshan Lu, Jie Yu, (unknown), Hang Zhang, Xiang‐Yang Ye	2
7	β-Elemene inhibits epithelial-mesenchymal transformation in non-small cell lung cancer by targeting ALDH3B2/RPSA axis 2024 ·Biochemical Pharmacology ·(unknown), Yanhua Kang, Yuan Gao, Xiang‐Yang Ye, Hang Zhang, Tian Xie	4
8	PARP7i Clinical Candidate RBN‐2397 Exerts Antiviral Activity by Modulating Interferon‐β Associated Innate Immune Response in Macrophages 2024 ·Drug Development Research ·Xiaoli Du, Jiawei Zhou, Yi Zhou, Yulong Chen, Yanhua Kang, Dongjiu Zhao, Xiang‐Yang Ye, Liwei Wang, Tian Xie, (unknown)	3
9	Determining optimal ALT cut‐off values for predicting significant hepatic histological changes in patients with normal ALT in the grey zone of chronic hepatitis B virus infection 2024 ·Alimentary Pharmacology & Therapeutics ·(unknown), (unknown), Qi Zheng, Xueping Yu, Airong Hu, Yue Guo, Huan Li, Xiang‐Yang Ye, (unknown), (unknown), (unknown), (unknown), (unknown), Chen Pan, Shanshan Liu, Jiming Zhang, Jiaji Jiang, (unknown)	1
10	Design, synthesis and anti-tumor efficacy evaluation of novel 1,3-diaryl propane-based polyphenols obtained from Claisen rearrangement reaction 2023 ·Bioorganic Chemistry ·(unknown), Xiang Qi, (unknown), Yuan Gao, (unknown), (unknown), Bing Xu, Shitang Ma, (unknown), Xiang‐Yang Ye, Zi Hui	2
11	Development a novel nomogram model for predicting significant hepatic histological changes in chronic hepatitis B virus carriers 2023 ·Journal of Medical Virology ·(unknown), (unknown), (unknown), (unknown), Xiang‐Yang Ye, Hui‐Ming Lin, (unknown), Shuo Lin, (unknown), (unknown), Jiaji Jiang, (unknown), Qi Zheng, Richeng Mao, (unknown)	2
12	Discovery of plant-derived anti-tumor natural products: Potential leads for anti-tumor drug discovery 2023 ·Bioorganic Chemistry ·Zi Hui, Hao Wen, Junlong Zhu, (unknown), Xiaoying Jiang, Xiang‐Yang Ye, Liwei Wang, Tian Xie, Renren Bai	46
13	Novel druggable mechanism of Parkinson's disease: Potential therapeutics and underlying pathogenesis based on ferroptosis 2023 ·Medicinal Research Reviews ·Xiaoying Jiang, (unknown), Xiang‐Yang Ye, Tian Xie, Pengfei Zhang, Benjamin E. Blass, Renren Bai	31
14	Design, synthesis and biological evaluation of novel histone deacetylase (HDAC) inhibitors derived from β -elemene scaffold 2023 ·Journal of Enzyme Inhibition and Medicinal Chemistry ·Yuan Gao, (unknown), (unknown), (unknown), Yu Wang, Xingrui He, Renren Bai, Xiang‐Yang Ye, Tian Xie	42
15	An updated patent review of protein arginine N-methyltransferase inhibitors (2019–2022) 2022 ·Expert Opinion on Therapeutic Patents ·Jinyun Dong, (unknown), Zi Hui, Carmen Garrido, Zhangshuang Deng, Tian Xie, Xiang‐Yang Ye	16
16	Discovery of small-molecule ATR inhibitors for potential cancer treatment: a patent review from 2014 to present 2022 ·Expert Opinion on Therapeutic Patents ·(unknown), Zi Hui, (unknown), Carmen Garrido, Tian Xie, Xiang‐Yang Ye	9
17	Races of small molecule clinical trials for the treatment of COVID‐19: An up‐to‐date comprehensive review 2021 ·Drug Development Research ·(unknown), (unknown), (unknown), Renren Bai, Xiang‐Yang Ye, Tian Xie	68
18	5-Hydroxymethylfurfural Alleviates Inflammatory Lung Injury by Inhibiting Endoplasmic Reticulum Stress and NLRP3 Inflammasome Activation 2021 ·Frontiers in Cell and Developmental Biology ·Hang Zhang, (unknown), Chuanbin Shen, Han Zou, Zhiping Zhang, Kaitao Wang, Renren Bai, Yanhua Kang, Xiang‐Yang Ye, Tian Xie	30
19	Small molecule DNA-PK inhibitors as potential cancer therapy: a patent review (2010–present) 2020 ·Expert Opinion on Therapeutic Patents ·(unknown), Zi Hui, Frédéric Lirussi, Carmen Garrido, Xiang‐Yang Ye, Tian Xie	44
20	4-Hydroxy-3-methylbenzofuran-2-carbohydrazones as novel LSD1 inhibitors 2020 ·Bioorganic & Medicinal Chemistry Letters ·Xingrui He, Yuan Gao, Zi Hui, Guodong Shen, Shuo Wang, Tian Xie, Xiang‐Yang Ye	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact